Group 1: Business Operations and Strategy - In 2025, the company optimized its offline sales channels and improved its management team, leading to enhanced operational capabilities and a solid foundation for 2026 [1] - The sales channels were shifted from traditional distribution to value-driven sales, resulting in a streamlined number of distributors and improved profitability [1] - The offline sales team is divided into three groups: CS and KA channels, professional channels, and OTC channels [1] Group 2: Financial Performance and Projections - Financial data for 2025 is still under audit, with specific figures to be disclosed in the annual report on April 23, 2026 [2] - The offline profit margin is higher than online, with improved profitability due to sales channel optimization [3] - The sales team has grown to over 200 members, reflecting ongoing recruitment efforts [4] Group 3: Product Development and Innovation - The company plans to continue its dual focus on medical devices and functional skincare products, with new product launches expected in various forms including dressings, masks, and creams [5] - Progress is being made on a recombinant type III humanized collagen freeze-dried fiber, which has completed clinical trials and is preparing for submission [6] Group 4: Corporate Governance and Future Plans - The company is considering mergers and acquisitions to enhance R&D capabilities and product offerings, with future updates to be disclosed as per regulatory requirements [7] - The dividend plan for this year has not yet been determined, with an announcement expected on April 23, 2026 [8] - There are ongoing considerations for stock incentive plans, with no current confirmation on implementation [9] - No share reductions have occurred from executives whose restrictions were lifted in February 2025 [9]
敷尔佳(301371) - 2026年3月13日投资者关系活动记录表（二）